Novavax to Participate in Fireside Chat at the 11th Annual SVB Leerink Global Healthcare Conference<\/p>\n
GAITHERSBURG, Md., Feb. 11, 2022 \/PRNewswire\/ --Novavax, Inc. (Nasdaq: NVAX), a biotechnology company dedicated to developing and commercializing next-generation vaccines for serious infectious diseases, today announced that it will participate in a fireside chat at the 11th Annual SVB Leerink Global Healthcare Conference. Novavax' recombinant nanoparticle protein-based COVID-19 vaccine candidate, NVX-CoV2373, will be a topic of discussion.<\/p>\n
Fireside chat details:<\/p>\n
Date:<\/p>\n
Wednesday, February 16, 2022<\/p>\n
Time:<\/p>\n
11:20 11:50 a.m. Eastern Savings Time (EST)<\/p>\n
Moderator:<\/p>\n
David Risinger<\/p>\n
Novavax participants:<\/p>\n
Filip Dubovsky, M.D., Executive Vice President, Chief Medical Officer and John J. Trizzino, Executive Vice President, Chief Commercial Officer and Chief Business Officer<\/p>\n
A replay of the recorded fireside session will be available through the events page of the Company's website at ir.novavax.com for 90 days.<\/p>\n
About Novavax<\/p>\n
Novavax, Inc. (Nasdaq: NVAX) is a biotechnology company that promotes improved health globally through the discovery, development and commercialization of innovative vaccines to prevent serious infectious diseases. The company's proprietary recombinant technology platform harnesses the power and speed of genetic engineering to efficiently produce highly immunogenic nanoparticles designed to address urgent global health needs. NVX-CoV2373, the company's COVID-19 vaccine, has received conditional authorization from multiple regulatory authorities globally, including the European Commission and the World Health Organization. The vaccine is also under review by multiple regulatory agencies worldwide. In addition to its COVID-19 vaccine, Novavax is also currently evaluating a COVID-seasonal influenza combination vaccine in a Phase 1\/2 clinical trial, which combines NVX-CoV2373 and NanoFlu, its quadrivalent influenza investigational vaccine candidate. These vaccine candidates incorporate Novavax' proprietary saponin-based Matrix-M adjuvant to enhance the immune response and stimulate high levels of neutralizing antibodies.<\/p>\n
For more information, visit http:\/\/www.novavax.comand<\/a> connect with us on LinkedIn.<\/p>\n Contacts: InvestorsNovavax, Inc. Erika Schultz | 240-268-2022ir@novavax.com<\/a> <\/p>\n Solebury TroutAlexandra Roy| 617-221-9197aroy@soleburytrout.com<\/a> <\/p>\n MediaAli Chartan | 240-720-7804Laura Keenan Lindsey | 202-709-7521media@novavax.com<\/a> <\/p>\n<\/p>\n<\/p>\n SOURCE Novavax, Inc.<\/p>\n <\/p>\n Read this article: Novavax to Participate in Fireside Chat at the 11th Annual SVB Leerink Global Healthcare Conference GAITHERSBURG, Md., Feb. Continue reading
\nNovavax to Participate in Fireside Chat at the 11th Annual SVB Leerink Global Healthcare Conference - Novavax Investor Relations<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"